Key facts
- It has raised $10.5M; the latest was Seed Round ($10.5M) in Mar 2026.
- Notable investors include NRW BANK, BiomedVC, Gründerfonds Ruhr, Khanu Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for iDEL Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for iDEL Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iDEL Therapeutics
Developer of a tumor-targeted intracellular delivery system intended to transport therapeutic payloads directly into the cytosol of cancer cells. The company's platform uses a synthetic shuttle mechanism that enables pan-cancer cellular uptake, high intracellular drug exposure, sustained tumor retention, compatibility with small and large molecules, including nanobody-based and cytotoxic payloads, and evasion of endosomal trapping, enabling oncology developers to access historically unreachable intracellular targets and broaden therapeutic application across diverse cancer types.
- Sector
- Healthcare
- HQ
- Dortmund, Germany
- Founded
- 2025
- Website
- idel-tx.com/
- Ownership
- Privately Held (backing)
iDEL Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iDEL Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iDEL Therapeutics in its N-PORT filings yet. We sweep new filings monthly.